This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dürig, J. Articles by Moritz, T. Search for Related Content PubMed PubMed Citation Articles by Dürig, J. Articles by Moritz, T.

A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease

Departments of ¹ Hematology, ² Internal Medicine (Cancer Research), and ³ Pathology and Neuropathology, and ⁴ Institute of Cell Biology, University of Duisburg-Essen Medical School, Essen, Germany and ⁵ Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Requests for reprints: Peter Ebeling, Department of Internal Medicine (Cancer Research), University of Duisburg-Essen Medical School, Hufelandstraße 55, 45122 Essen, Germany. Phone: 49-201-723-3120; Fax: 49-201-723-2735; E-mail: peter.ebeling{at}uni-due.de.

We here describe a novel xenograft model of chronic lymphocytic leukemia (CLL) generated by infusion of human primary CLL cells into immunodeficient nonobese/severe combined immunodeficient (NOD/SCID) mice. Combined i.v. and i.p. injection of peripheral blood mononuclear cells (PBMC) from 39 patients with CLL resulted in highly reproducible splenic (37 of 39) and peritoneal (35 of 39) engraftment, which remained stable over a time span of 4 to 8 weeks. By comparison, recovery of leukemic cells from bone marrow (21 of 39) or peripheral blood (8 of 22) was substantially lower. The engraftment pattern of CLL PBMC 4 weeks posttransplant was correlated with clinical disease activity: infusion of PBMC from donors with Binet stage A, lymphocyte doubling time of >12 months, and normal lactate dehydrogenase (LDH) serum levels led to marked engraftment of T cells whereas comparably few tumor cells could be detected. In contrast, NOD/SCID mice receiving PBMC from donors with advanced stage Binet C, lymphocyte doubling time of <12 months, and elevated LDH serum levels exhibited predominant engraftment of tumor cells and comparably low numbers of T cells. These results suggest that this model reflects the heterogeneity and important clinical characteristics of the disease, and thus may serve as a tool for preclinical drug testing and investigation of the pathophysiology of CLL. [Cancer Res 2007;67(18):8653–61]

This article has been cited by other articles:

				D. Trachootham, H. Zhang, W. Zhang, L. Feng, M. Du, Y. Zhou, Z. Chen, H. Pelicano, W. Plunkett, W. G. Wierda, et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism Blood, September 1, 2008; 112(5): 1912 - 1922. [Abstract] [Full Text] [PDF]